Clinical Trial

CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma

Study acronym: CARTHEDRALL
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this prospective, multicentric, single-arm, phase I/II clinical trial is to evaluate the safety and efficacy of a novel CD19-directed CAR-T cell locally produced in an academic institution in Brazil in patients with refractory or relapsed acute lymphoblastic leukemia or non-Hodgkin lymphoma. Participants will receive a single intravenous infusion of an autologous academic anti-CD19 CAR-T cell and will be followed for 5 years.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-10-23.
Status change: Not Yet Recruiting → Recruiting 2024-12-04
Trial Details
NCT Number NCT06101381
Lead Sponsor University of Sao Paulo
Collaborators: Blood Center of Ribeirao Preto, Hospital das Clínicas de Ribeirão Preto
Conditions Leukemia, Acute Lymphoblastic, Lymphoma, Non-Hodgkin
Enrollment 81 participants
Start Date 2024-03-21
Primary Completion 2028-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2024-12-09